DALVANCE (Durata Therapeutics Inc.)
Welcome to the PulseAid listing for the DALVANCE drug offered from Durata Therapeutics Inc.. This Lipoglycopeptide Antibacterial [EPC],Lipoglycopeptides [Chemical/Ingredient] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Durata Therapeutics Inc. |
NON-PROPRIETARY NAME: | Dalbavancin |
SUBSTANCE NAME: | DALBAVANCIN HYDROCHLORIDE |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Lipoglycopeptide Antibacterial [EPC],Lipoglycopeptides [Chemical/Ingredient] |
ROUTE: | INTRAVENOUS |
DOSAGE FORM: | INJECTION, POWDER, FOR SOLUTION |
MARKETING CATEGORY NAME: | NDA |
START MARKETING DATE: | 2014-05-23 |
END MARKETING DATE: | 0000-00-00 |
DALVANCE HUMAN PRESCRIPTION DRUG Details:
Item Description | DALVANCE from Durata Therapeutics Inc. |
LABELER NAME: | Durata Therapeutics Inc. |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 500(mg/25mL) |
START MARKETING DATE: | 2014-05-23 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 57970-100_7dcea8f6-ed83-4355-b2a7-54f6dd079125 |
PRODUCT NDC: | 57970-100 |
APPLICATION NUMBER: | NDA021883 |
Other DALBAVANCIN HYDROCHLORIDE Pharmaceutical Manufacturers / Labelers: